Apr 11, 2024

Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting

➞

Apr 03, 2024

MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China

➞

Mar 25, 2024

Mabwell ranks on the list of 2024 Top 100 Hardcore Technology Enterprises in Shanghai

➞

Mar 18, 2024

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

➞

Mar 18, 2024

SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential

➞

Mar 15, 2024

Mabwell has been included in the FTSE Russell Global Equity Index Series

➞

Mar 11, 2024

Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London

➞

Mar 07, 2024

Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting

➞

Mar 07, 2024

Mabwell's Expanded Access Policy for 9MW2821

➞

Mar 06, 2024

Mabwell to Present the Clinical Data of 9MW2821 in Cervical Cancer as Focused Plenary Oral Presentation at 2024 Society of Gynecologic Oncology Annual Meeting on Women's Cancer

➞